Begin main content

Tecentriq for Small Cell Lung Cancer – Details

Project Number pCODR 10156
Brand Name Tecentriq
Generic Name Atezolizumab
Tumour Type Lung
Indication Small Cell Lung Cancer (SCLC)
Funding Request In combination with etoposide and a platinum-based chemotherapy for the first line treatment of patients with extensive stage small cell lung cancer (SCLC). Maintenance TECENTRIQ should be continued until loss of clinical benefit or unacceptable toxicity.
Review Status Pending
Pre Noc Submission Yes
NOC Date
Manufacturer Hoffmann-La Roche Limited
Submitter Hoffmann-La Roche Limited
Submission Date (Target Date) March 4, 2019
Submission Type New Indication
Prioritization Requested
Stakeholder Input Deadline (target date based on target submission date) ‡ March 18, 2019
Check-point meeting (target date)
pERC Meeting (target date)
Initial Recommendation Issued (target date)
Feedback Deadline (target date) ‡
pERC Reconsideration Meeting (target date)
Final Recommendation Issued (target date)
Notification to Implement Issued

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.